Logo image of PLRX

PLIANT THERAPEUTICS INC (PLRX) Stock Fundamental Analysis

NASDAQ:PLRX - Nasdaq - US7291391057 - Common Stock - Currency: USD

1.23  +0.07 (+6.03%)

Fundamental Rating

1

PLRX gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 195 industry peers in the Pharmaceuticals industry. While PLRX seems to be doing ok healthwise, there are quite some concerns on its profitability. PLRX has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year PLRX has reported negative net income.
In the past year PLRX has reported a negative cash flow from operations.
PLRX had negative earnings in each of the past 5 years.
PLRX had a negative operating cash flow in each of the past 5 years.
PLRX Yearly Net Income VS EBIT VS OCF VS FCFPLRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M

1.2 Ratios

PLRX's Return On Assets of -63.67% is on the low side compared to the rest of the industry. PLRX is outperformed by 65.13% of its industry peers.
PLRX has a Return On Equity of -85.36%. This is comparable to the rest of the industry: PLRX outperforms 44.10% of its industry peers.
Industry RankSector Rank
ROA -63.67%
ROE -85.36%
ROIC N/A
ROA(3y)-39.89%
ROA(5y)-35.54%
ROE(3y)-47.53%
ROE(5y)-41.22%
ROIC(3y)N/A
ROIC(5y)N/A
PLRX Yearly ROA, ROE, ROICPLRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for PLRX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PLRX Yearly Profit, Operating, Gross MarginsPLRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 -2K -4K -6K -8K -10K

More info and screens

4

2. Health

2.1 Basic Checks

PLRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, PLRX has more shares outstanding
Compared to 5 years ago, PLRX has more shares outstanding
Compared to 1 year ago, PLRX has a worse debt to assets ratio.
PLRX Yearly Shares OutstandingPLRX Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
PLRX Yearly Total Debt VS Total AssetsPLRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

Based on the Altman-Z score of -3.89, we must say that PLRX is in the distress zone and has some risk of bankruptcy.
PLRX's Altman-Z score of -3.89 is in line compared to the rest of the industry. PLRX outperforms 42.05% of its industry peers.
A Debt/Equity ratio of 0.12 indicates that PLRX is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.12, PLRX is in line with its industry, outperforming 47.18% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.12
Debt/FCF N/A
Altman-Z -3.89
ROIC/WACCN/A
WACC10.17%
PLRX Yearly LT Debt VS Equity VS FCFPLRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M

2.3 Liquidity

PLRX has a Current Ratio of 11.03. This indicates that PLRX is financially healthy and has no problem in meeting its short term obligations.
PLRX has a Current ratio of 11.03. This is amongst the best in the industry. PLRX outperforms 84.10% of its industry peers.
PLRX has a Quick Ratio of 11.03. This indicates that PLRX is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of PLRX (11.03) is better than 84.10% of its industry peers.
Industry RankSector Rank
Current Ratio 11.03
Quick Ratio 11.03
PLRX Yearly Current Assets VS Current LiabilitesPLRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

1

3. Growth

3.1 Past

PLRX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -25.78%.
The Revenue for PLRX has decreased by -100.00% in the past year. This is quite bad
EPS 1Y (TTM)-25.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-17.95%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

PLRX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 21.79% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y25.46%
EPS Next 2Y19.9%
EPS Next 3Y19.06%
EPS Next 5Y21.79%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
PLRX Yearly Revenue VS EstimatesPLRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
PLRX Yearly EPS VS EstimatesPLRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

PLRX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PLRX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PLRX Price Earnings VS Forward Price EarningsPLRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PLRX Per share dataPLRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

PLRX's earnings are expected to grow with 19.06% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y19.9%
EPS Next 3Y19.06%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for PLRX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PLIANT THERAPEUTICS INC

NASDAQ:PLRX (7/1/2025, 12:23:37 PM)

1.23

+0.07 (+6.03%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-08 2025-05-08/amc
Earnings (Next)08-05 2025-08-05/amc
Inst Owners100.09%
Inst Owner Change-9.78%
Ins Owners2.46%
Ins Owner Change2.97%
Market Cap75.51M
Analysts69.47
Price Target4.88 (296.75%)
Short Float %5.66%
Short Ratio2.94
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-3.17%
Min EPS beat(2)-24.53%
Max EPS beat(2)18.2%
EPS beat(4)2
Avg EPS beat(4)-2.19%
Min EPS beat(4)-24.53%
Max EPS beat(4)18.2%
EPS beat(8)6
Avg EPS beat(8)3.03%
EPS beat(12)9
Avg EPS beat(12)3.35%
EPS beat(16)11
Avg EPS beat(16)3.13%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-70.77%
EPS NQ rev (1m)-1.61%
EPS NQ rev (3m)-16.4%
EPS NY rev (1m)-6.4%
EPS NY rev (3m)32.9%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-36.5%
Revenue NY rev (3m)62.98%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.29
P/tB 0.29
EV/EBITDA N/A
EPS(TTM)-3.61
EYN/A
EPS(NY)-1.95
Fwd EYN/A
FCF(TTM)-2.88
FCFYN/A
OCF(TTM)-2.84
OCFYN/A
SpS0
BVpS4.19
TBVpS4.19
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -63.67%
ROE -85.36%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-39.89%
ROA(5y)-35.54%
ROE(3y)-47.53%
ROE(5y)-41.22%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.12
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 127.09%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 11.03
Quick Ratio 11.03
Altman-Z -3.89
F-Score1
WACC10.17%
ROIC/WACCN/A
Cap/Depr(3y)109.27%
Cap/Depr(5y)114.25%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-25.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-17.95%
EPS Next Y25.46%
EPS Next 2Y19.9%
EPS Next 3Y19.06%
EPS Next 5Y21.79%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-20.81%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year47.22%
EBIT Next 3Y16.71%
EBIT Next 5YN/A
FCF growth 1Y-67.2%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-66.74%
OCF growth 3YN/A
OCF growth 5YN/A